Veterinary care providers recognize clinical utility of genetic testing but report limited confidence in interpreting...

Direct-to-consumer (D2C) genetic tests are increasingly accessible to pet owners, with commercial genetic companies entering veterinary distribution markets. This study evaluated veterinary care providers' (VCPs) awareness of the D2C genetic industry, experiences with clients' inquiries, perceptions of clinical utility, and confidence in interpreting test results.

Veterinary care providers attending a professional conference (February 19 through 23, 2023) were invited to complete an online survey.

229 VCPs began the survey, and 218 completed all sections. Respondents were predominately veterinarians (131 of 218 [60.3%]), mostly working in small animal practices (160 of 218 [73.7%]), with dogs (206 of 218 [94.9%]) and cats (199 of 218 [91.7%]). 186 of 229 participants (81.2%) encountered clients using or intending to use D2C genetic tests, often seeking recommendations or the VCP's opinion about genetic services. 86 of 131 veterinarians (65.6%) and 36 of 44 registered veterinary technicians (81.8%) perceived genetic testing as clinically useful. Veterinarians reported higher confidence in interpreting dog than cat results, with additional differences related to breed versus health information.

This study indicates that VCPs are generally aware of D2C genetic testing, with licensed veterinarians and veterinary technicians recognizing its clinical utility. However, veterinarian confidence levels with assisting clients in understanding their results varies by species and test type.

As trends in D2C genetic testing persist, there is a need for interventions to address the lack of guidelines and improve VCP attitudes and confidence in assisting clients with these tests. This will involve genetic companies offering targeted support and continuing education to address gaps in confidence related to dog, cat, breed, and health information.